person · Reporting owner
Tucker Edwin Jonathan
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Chief Medical Officer | June 04, 2025 | June 06, 2025 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Chief Medical Officer | November 10, 2021 | November 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jasper Therapeutics, Inc.
Report date June 04, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2035-06-04 | Direct | 90,000 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: 1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Mirum Pharmaceuticals, Inc.
Report date November 10, 2021 · Filed November 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,838 |
Reported balance
After 2021-11-10 transaction · row 1
1 source rowRow 1 · 2021-11-10 · Grant · Acquired 70 · Balance 45,838 F1: This Form 4 is being filed voluntarily to report the acquisition of 70 shares by the Reporting Person on November 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed voluntarily to report the acquisition of 70 shares by the Reporting Person on November 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2025 Filed Jun 6, 2025 10:23 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001213900-25-051722 · ownership.xml · derivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Voting Common Stock · 90,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:29 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001213900-25-014948 · ownership.xml · derivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Voting Common Stock · 50,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 22:31 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantVoting Common Stock | 400 | $4.17 | $1,669.40 |
DisclosureSEC source: 0001213900-24-051417 · ownership.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 00:22 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001213900-24-015457 · ownership.xml · derivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Voting Common Stock · 45,000 shares Expires 2034-02-15 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 00:45 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001213900-23-048681 · ownership.xml · derivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Voting Common Stock · 400,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 12, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 21:23 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 70 | $13.52 | $946.05 |
DisclosureSEC source: 0001209191-21-064453 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,838 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 70 shares by the Reporting Person on November 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 01, 2021 Filed Oct 2, 2021 00:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,364 | $19.26 | $26,264.91 |
DisclosureSEC source: 0001209191-21-058604 · doc4.xml · nonDerivative · entry 2 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,768 F2 · shares: Shares sold to cover tax withholding obligations associated with the vesting of the performance-based restricted stock unit award granted to the Reporting Person on March 9, 2021. Read SEC document |
| September 29, 2021 Filed Oct 2, 2021 00:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058604 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,132 F1 · shares: The shares became issuable upon the satisfaction of certain performance conditions that were established at the time of the Compensation Committee's approval of a performance-based restricted stock unit award on March 9, 2021. On September 29, 2021, the Compensation Committee certified the achievement of the performance criteria resulting in the vesting of 4,062 shares on September 29, 2021 and 4,063 shares on June 30, 2023. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:46 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,483 | $14.62 | $21,681.46 |
DisclosureSEC source: 0001209191-21-032163 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,007 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,483 shares by the Reporting Person on May 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 23:40 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 1,082 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-21-018717 · doc4.xml · derivative · entry 2 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,751 Underlying: Common Stock · 1,082 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares vest one year after October 24, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of October 24, 2019. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 23:40 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 1,082 | $7.70 | $8,331.40 |
DisclosureSEC source: 0001209191-21-018717 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:14 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001209191-21-002988 · doc4.xml · derivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-01-06 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 21:24 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 4,167 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-20-065367 · doc4.xml · derivative · entry 2 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,833 Underlying: Common Stock · 4,167 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares vest one year after October 24, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of October 24, 2019. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 21:24 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 4,167 | $7.70 | $32,085.90 |
DisclosureSEC source: 0001209191-20-065367 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:12 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,275 | $15.27 | $19,464.15 |
DisclosureSEC source: 0001209191-20-058044 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,275 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,275 shares by the Reporting Person on November 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:09 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-20-056690 · doc4.xml · derivative · entry 2 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares vest one year after October 24, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of October 24, 2019. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 22:09 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 25,000 | $7.70 | $192,500.00 |
DisclosureSEC source: 0001209191-20-056690 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This Form 4 is being filed to report an option exercise and hold transaction that does not involve any open market purchase and sale. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 20:47 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 2,500 | $11.90 | $29,740.00 |
DisclosureSEC source: 0001209191-20-020665 · doc4.xml · nonDerivative · entry 2 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · price: The weighted average purchase price for the transaction reported was $11.896, and the range of prices were between $11.88 and $11.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 20:47 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 2,000 | $9.91 | $19,818.00 |
DisclosureSEC source: 0001209191-20-020665 · doc4.xml · nonDerivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:43 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $19.24 | $0.00 |
DisclosureSEC source: 0001209191-20-003345 · doc4.xml · derivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 10, 2020 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:17 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-19-054240 · doc4.xml · derivative · entry 1 Tucker Edwin Jonathan · CIK 0001792296 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-10-23 F1 · derivative.exercise_date: 1/4th of the shares vest one year after October 24, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of October 24, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.